T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation

Background. We have previously shown that CD8 depletion or CD34 selection of peripheral blood stem cells (PBSC) reduced the incidence of acute graft-versus-host disease (GvHD) after nonmyeloablative stem-cell transplantation (NMSCT). In this study, we analyze the effect of CD8 depletion or CD34 selection of the graft on early T-cell reconstitution. Methods. Nonmyeloablative conditioning regimen consisted in 2 Gy total-body irradiation (TBI) alone, 2 Gy TBI and fludarabine, or cyclophosphamide and fludarabine. Patients 1 to 18 received unmanipulated PBSC, patients 19 to 29 CD8-depleted PBSC, and patients 30 to 35 CD34-selected PBSC. Results. T-cell counts, and particularly CD4+ and CD4CD45RA+ counts, remained low the first 6 months after nonmyeloablative stem-cell transplantation (NMSCT) in all patients. CD34 selection (P <0.0001) but not CD8 depletion of PBSC significantly decreased T-cell chimerism. Donor T-cell count was similar in unmanipulated compared with CD8-depleted PBSC recipients but was significantly lower in CD34-selected PBSC recipients (P =0.0012). T cells of recipient origin remained stable over time in unmanipulated and CD8-depleted PBSC patients but expanded in some CD34-selected PBSC recipients between day 28 and 100 after transplant. Moreover, whereas CD8 depletion only decreased CD8+ counts (P <0.047), CD34 selection reduced CD3+(P <0.001), CD8+(P <0.016), CD4+ (P <0.001), and CD4+CD45RA+ (P <0.001) cell counts. T-cell repertoire was restricted in all patients on day 100 after hematopoietic stem-cell transplantation but was even more limited after CD34 selection (P =0.002). Conclusions. Despite of the persistence of a significant number of T cells of recipient origin, T-cell counts were low the first 6 months after NMSCT. Moreover, contrary with CD8 depletion of the graft that only affects CD8+ lymphocyte counts, CD34 selection dramatically decreased both CD8 and CD4 counts.

[1]  F. Baron,et al.  Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update. , 2003, Haematologica.

[2]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[3]  R. Storb.  Allogeneic hematopoietic stem cell transplantation--yesterday, today, and tomorrow. , 2003, Experimental hematology.

[4]  A. Foster,et al.  Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  Y. Beguin,et al.  Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  D. Rizzieri,et al.  Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  F. Baron,et al.  Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells. , 2002, Journal of hematotherapy & stem cell research.

[8]  Y. Beguin,et al.  Nonmyeloablative allogeneic hematopoietic stem cell transplantation. , 2002, Journal of hematotherapy & stem cell research.

[9]  M. Maris,et al.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. , 2002, Blood.

[10]  J. Bourhis,et al.  Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. , 2002, Blood.

[11]  F. Baron,et al.  Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. , 2002, Haematologica.

[12]  J. Wagner,et al.  Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  R. Soiffer,et al.  The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[14]  J. Gribben,et al.  T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. , 2001, Blood.

[15]  R. Storb,et al.  Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. , 2001, Blood.

[16]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[17]  Y. Beguin,et al.  Adoptive immunotherapy with donor lymphocyte infusionsafter allogeneic HPC transplantation , 2000, Transfusion.

[18]  D. Neuberg,et al.  Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. , 2000, Blood.

[19]  R. Storb,et al.  Mixed chimerism: preclinical studies and clinical applications. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[21]  N. Young,et al.  T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect , 1998, Bone Marrow Transplantation.

[22]  B. Chapuis,et al.  Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. , 1996, Blood.

[23]  H. Kantarjian,et al.  CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1995, Blood.

[24]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[25]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[26]  T. Reichert,et al.  SELECTIVE DEPLETION OF CD8+ CELLS FOR PREVENTION OF GRAFT‐VERSUS-HOST DISEASE AFTER BONE MARROW TRANSPLANTATION A RANDOMIZED CONTROLLED TRIAL , 1994, Transplantation.

[27]  S. Roman-Roman,et al.  An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction , 1992, European journal of immunology.